Ally Bridge Group’s Stoke Therapeutics STOK Stock Holding History

Ally Bridge Group’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-175,000	Closed	-$2.31M	–	45
2022 Q2	$2.31M	Hold	175,000	–	–	2.11%	21
2022 Q1	$3.68M	Sell	175,000 -10,000	-5%	-$200K	2.73%	18
2021 Q4	$4.44M	Buy	+185,000	New	+$4.41M	1.55%	26

Other funds holding STOK

Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Ally Bridge Group's STOK Position: Q3 2022 in Review

Ally Bridge Group sold out of Stoke Therapeutics (STOK) in Q3 2022, closing a stake of 175,000 shares — an estimated $2.31M sold.

Ally Bridge Group first reported a position in STOK in Q4 2021 and held it in 3 quarters. The position peaked at $4.44M in Q4 2021. 105 funds tracked by Wall St. Rank hold STOK as of Q3 2022.

Ally Bridge Group reported no remaining Stoke Therapeutics position as of Q3 2022 after selling out during the quarter.
Ally Bridge Group sold 175,000 Stoke Therapeutics shares in Q3 2022, an estimated $2.31M.
Ally Bridge Group first reported a position in Stoke Therapeutics in Q4 2021 and held it in 3 quarters.
Ally Bridge Group's Stoke Therapeutics position peaked at $4.44M in Q4 2021.
105 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2022.

Based on Ally Bridge Group's 13F filing for Q3 2022, filed 14 Nov 2022.